Skip to content

Detection of ovarian cancer specific gene mutation in uterine secretion using LiquidSCAN

Detection of ovarian cancer specific gene mutation in uterine secretion using LiquidSCAN

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0007000
Enrollment
44
Registered
2022-02-11
Start date
2022-04-01
Completion date
Unknown
Last updated
2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Chung-Ang Univerisity Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Normal group 1. A woman between the ages of 20 and 70 who came to the hospital for routine examination 2. A woman who has no abnormal findings in the endometrium or ovaries on ultrasound at the examination and normal PAP test within the last 2 years(if there is uterine fibroids or adenomyosis, it may be included in the this group) Benign ovarian cyst group 1. Women between the ages of 20 and 70 2. A woman who has no abnormal findings in the endometrium or ovaries on ultrasound, and normal PAP test within the last 2 years. (if there is uterine fibroids or adenomyosis, it may be included in this group) 3. Imaging (US or MRI or CT), tumor marker level, or clinically not suspected ovarian cancer, fallopian tube cancer, or primary peritoneal cancer 4. Patients whose ovaries or fallopian tubes are included in the surgical procedure.

Exclusion criteria

Exclusion criteria: 1. Patients who have previously had bilateral salpingectomy 2. Patients who underwent tubal ligation for the purpose of contraception 3. Patients who have received chemotherapy, radiotherapy, biological treatment, or drugs in clinical trials after being diagnosed with ovarian cancer 4. Patients diagnosed with ovarian, fallopian, primary peritoneal cancer or metastasis of cancer to other organs in the final pathological examination.

Design outcomes

Primary

MeasureTime frame
ovarian cancer specific gene mutation

Secondary

MeasureTime frame
diagnostic performance of ovarian cancer specific gene

Countries

Korea, Republic of

Contacts

Public ContactHyun Jin Choi

Chung-Ang University

hj0818.choi@gmail.com+82-2-6299-1660

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026